This page contains exclusive content for the member of the following sections: TID
Presenter: Michele I., Morris, Miami, United States
Authors: Michele I. Morris
Transplant recipients are at significantly higher risk of tuberculosis when compared to the general population. Tuberculosis post-transplant may have an atypical presentation and is often disseminated at the time of diagnosis. Delays in diagnosis may account for some of the increased morbidity and mortality observed. Identifying and treating latent tuberculosis in transplant candidates may decrease the risk of post-transplant TB. An understanding of the potential drug toxicities and drug-drug interactions associated with anti-mycobacterial therapy is essential to manage latent or active TB in the transplant patient. Careful patient monitoring as well as close collaboration between the transplant team and the infectious disease specialist or TB professional is required for successful graft and patient outcomes. This talk will review some of the most common challenges faced in treating latent and active tuberculosis in transplant patients.
By viewing the material on this site you understand and accept that:
The Transplantation Society
505 Boulevard René-Lévesque Ouest
Montréal, QC, H2Z 1Y7